clinical trial · NCT05779241
Study to Evaluate the Pharmacokinetics (PK) and Safety/Tolerability of Long-Acting Oral LYN-005
SchizophreniaSchizoaffective DisorderLYN-005Risperidone
brief summary
Lyndra Therapeutics, Inc. is developing LYN-005, a long-acting oral (LAO) capsule (LYNX™ dosage form) of risperidone. This pivotal study (LYN-005-C-301) will evaluate the PK as well as safety and tolerability of multiple administrations of the LYN-005 formulation at two dose levels.
started
Apr 13, 2023
primary completion
Nov 3, 2023
completion
Dec 1, 2023
last updated
Oct 24, 2024
official title
A Multi Dose, Open-Label, Parallel-Group Study to Evaluate the PK and Safety/Tolerability of Long-Acting Oral Risperidone (LYN-005) in Participants With Schizophrenia or Schizoaffective Disorder
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol